Stock Taper
SCREENER COMPARE ANY 2 STOCKS
PBM
PSYENCE BIOMEDICAL LTD.
NASDAQ
$4.33
▲ UP 10.18% (0.40)

KEY STATISTICS

Market Cap$82.35 K
52w High$216.41
52w Low$1.92
Dividend Yield—
Frequency—
P/E-0.01
Volume103.39K
Shares Out.19.02K

COMPANY

LEADERSHIP

Jody Aufrichtig
CHIEF EXECUTIVE
Jody Aufrichtig

ABOUT

SECTOR
Healthcare
WENT PUBLIC
December 10, 2021
METHOD OF GOING PUBLIC
N/A
FULL TIME EMPLOYEES
12

SPLIT RECORD

DATETYPERATIO
2026-02-02Reverse1:6
2026-01-20Reverse1:6
2025-05-05Reverse1:8
2024-11-26Reverse1:75

PRICE

$4.33 ▲ UP 10.18% (+$0.40)
OVERLAYS
$4.05$4.20$4.359:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM4.33

About Psyence Biomedical Ltd.

https://www.psyencebiomed.com ↗

Psyence Biomedical Ltd. develops botanical psilocybin-based medicines, with its lead candidate PEX010 in Phase IIb for treating anxiety, depression, and adjustment disorder in palliative care patients, through partnerships and clinical trials.

INDUSTRY

Biotechnology

A PRODUCT PSYENCE BIOMEDICAL LTD. IS KNOWN FOR

NPX5
NPX5

NPX5, a clinical-stage, nature-derived psilocybin developed by Psyence Biomedical, is in Phase IIb trials for treating Adjustment Disorder in cancer patients within palliative care.

COMPETITORS

COMPETITOR
ATAI COMPARE
CMPS COMPARE
GHRS COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
1
LISTED HERE
1
RANKED BY POSITION SIZE
PSIL
1.32% · 175.7K

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow5
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book3
Overall Score2

SECTORS PEERS

PEERPRICE
INDP$1.29COMPARE
GTBP$0.29COMPARE
REVB$1.09COMPARE
ELAB$6.66COMPARE
PTIX$0.80COMPARE
DRMA$1.42COMPARE
NKGN$0.01COMPARE
SPRC$6.70COMPARE